SCHEMBL924709

SCHEMBL924709

CCCCC(CC)C(=O)OOC(C)(C)CCC(C)(OOC(=O)C(CC)CCCC)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.47
CA1 P00915 4/20 0.47
MAPK1 P28482 2/20 0.44
ATM Q13315 2/20 0.36
GAA P10253 1/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PDF Q9HBH1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Peroxide SCHEMBL15855960 0.91 CA2 (0.56) CA2CA1MAPK1ATMGAA
SCHEMBL57471 0.90 CA2 (0.58) CA2CA1MAPK1ATMGAA
SCHEMBL10714547 0.85 CA2 (0.56) CA2CA1MAPK1ATMGAA
SCHEMBL12140593 0.85 CA2 (0.56) CA2CA1MAPK1ATMGAA
SCHEMBL21081722 0.84 CA2 (0.50) CA2CA1MAPK1ATMGAA
SCHEMBL31486196 0.82 CA2 (0.49) CA2CA1MAPK1ATMGAA
SCHEMBL8729030 0.81 CA2 (0.51) CA2CA1MAPK1ATMGAA
SCHEMBL28324938 0.81 CA2 (0.47) CA2CA1MAPK1ATMGAA
SCHEMBL218700 0.81 CA2 (0.58) CA2CA1MAPK1ATMGAA
SCHEMBL38657779 0.80 CA2 (0.41) CA2CA1MAPK1ATMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577432-B2 Organosilicon compound, production method therefor, and curable composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-03-17 US disclosed
EP-4282653-B1 ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION SHINETSU CHEMICAL CO (JP) 2026-02-25 EP disclosed
US-12522684-B2 Active-energy-ray-curable resin composition and cured product thereof NIPPON SHOKUBAI CO., LTD. (JP) 2026-01-13 US disclosed
EP-4159779-B1 ACTIVE-ENERGY-RAY-CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF NIPPON CATALYTIC CHEM IND (JP) 2025-12-10 EP disclosed
US-20240101723-A1 METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE POLYMER LATEX ZEON CORPORATION (JP) 2024-03-28 US disclosed
US-20240059929-A1 ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-02-22 US disclosed
EP-4299272-A1 METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE POLYMER LATEX Zeon Corporation (JP) 2024-01-03 EP disclosed
WO-2023238925-A1 RADICAL POLYMERIZABLE COMPOSITION AND POLYMERIZED PRODUCT THEREOF 株式会社日本触媒 2023-12-14 WO disclosed
EP-4282653-A1 ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-11-29 EP disclosed
WO-2023167186-A1 POLYMERIZABLE COMPOSITION 株式会社日本触媒 2023-09-07 WO disclosed
EP-2626374-A1 DIENE-BASED CARBOXYLATE ANION AND SALT THEREOF, AND POLYMERIZABLE OR CURABLE COMPOSITION THEREOF Nippon Shokubai Co., Ltd. (JP) 2013-08-14 EP disclosed
US-20130197123-A1 DIENE-BASED CARBOXYLATE ANION AND SALT THEREOF, AND POLYMERIZABLE OR CURABLE COMPOSITION THEREOF NIPPON SHOKUBAI CO., LTD. (JP) 2013-08-01 US disclosed
US-8399583-B2 Polymer, curable resin composition, cured product, and article NIPPON SHOKUBAI CO., LTD. (JP) 2013-03-19 US disclosed
US-20110009586-A1 POLYMER, CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ARTICLE NIPPON SHOKUBAI CO., LTD. (JP) 2011-01-13 US disclosed
EP-1569013-B1 Curable composition for optical parts NIPPON CATALYTIC CHEM IND (JP) 2010-04-14 EP disclosed
EP-1772471-B1 Radiation-curable composition and cured product thereof NIPPON CATALYTIC CHEM IND (JP) 2010-03-03 EP disclosed
EP-1772471-A1 Radiation-curable composition and cured product thereof Nippon Shokubai Co.,Ltd. (JP) 2007-04-11 EP disclosed
US-20070049655-A1 Radiation-curable composition and cured product thereof NIPPON SHOKUBAI CO., LTD. (JP) 2007-03-01 US disclosed
US-20050192373-A1 Curable composition for optical parts NIPPON SHOKUBAI CO., LTD. 2005-09-01 US disclosed
EP-1569013-A2 Curable composition for optical parts NIPPON SHOKUBAI CO., LTD. (JP) 2005-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577432-B2 Organosilicon compound, production method therefor, and curable composition ASH2L, DOT1L, DNMT3L CA2 145/4885CA1 13/4885MAPK1 2998/4885
US-20240059929-A1 ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION CYP51A1, CYP4F11, FAR1 CA2 1662/4885CA1 883/4885MAPK1 3528/4885
US-20130197123-A1 DIENE-BASED CARBOXYLATE ANION AND SALT THEREOF, AND POLYMERIZABLE OR CURABLE COMPOSITION THEREOF MIF, DCTN1, CDH1 CA2 64/4885CA1 40/4885MAPK1 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.